JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma
ConditionB-cell Non-Hodgkin's Lymphoma
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-80
SponsorShanghai Junshi Bioscience Co., Ltd.
About this trial
To evaluate the preliminary efficacy of JS203 combined with standard regimens in patients with B-cell Non-Hodgkin's lymphoma
Eligibility criteria
Qualifiers
Age range: 18 to 80 years old (inclusive), both male and female are acceptable；
ECOG: 0-2；
B-cell non-Hodgkin's lymphoma expressing CD20 antigen that has been pathologically diagnosed；
At least one measurable lesion meeting the criteria specified in the Lugano 2014 response assessment； Acceptable organ function at screening；
Disqualifiers
A history of severe allergy to monoclonal antibody therapy (or recombinant antibody-related fusion protein)；
Previously received CD20-CD3 bispecific antibody treatment；
Previous allogeneic hematopoietic stem cell transplantation；
Previous solid organ transplantation；
Trial design
Treatments tested in this trial
- JS203 in combination with gemcitabine and oxaliplatin
- JS203 in combination with ifosfamide, carboplatin and etoposide
- JS203 in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone
- JS203 combined with lenalidomide
Treatment groups
180 Participants
are divided into 6 treatment groups6
Treatment groupsSee each treatment group below.
Sponsors and collaborators
Source ClinicalTrials.gov